Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 28/09/18 at 11:39am

Life expectancy was a key topic this week, as it emerged that growth has stalled and even fallen in areas of the US and UK, while the NHS secured support from UK courts after Novartis and Bayer attempted to block its decision to utilise cheaper treatments for wet age-related macular degeneration.

But the most popular story of the week, unsurprisingly, was the news that Novartis is set to cull 2,500 positions from its global workforce form locations in the UK and Switzerland, as part of wider efforts to streamline the business.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Life expectancy falls in America; drugs, alcohol and suicide to blame

Life expectancy has fallen for the second year in a row for people in the United States, according to new data released by Centers for Disease Control and Prevention in Atlanta.

9. Life expectancy falls in Scotland for first time in 35 years

Life expectancy has fallen for the first time in 35 years in Scotland, as data released by the National Records of Scotland has revealed that life expectancy fell by 0.1 years for both men and women in the constituent country of the United Kingdom.

8. AstraZeneca's Farxiga cuts heart risk in type 2 diabetes patients

AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings in the in improving cardiovascular (CV) outcomes vs placebo in patients with type 2 diabetes (T2B) and multiple CV risk factors or established disease.

7. J&J pledges to end global TB pandemic

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s most deadly infectious disease.

6. Courts back NHS in fight against Novartis and Bayer

The NHS has won a court case against multinational pharmaceutical firms Novartis and Bayer, after the companies sought to block Britain’s National Health Service from using a much cheaper drug to treat the leading cause of blindness, wet age-related macular degeneration (wet AMD).

5. EU approval for Mylan and Fujifilm's Humira biosimilar

The European Commission has approved its fifth biosimilar of the world’s best-selling drug, Abbvie’s Humira (adalimumab), granting marketing authorisation to Mylan and Fujifilm Kyowa Kirin Biologics’ (FFKB) Hulio.

4. NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE's decision making process

Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, according to the London-based data analytics firm GlobalData.

3. AstraZeneca CEO suggests he's the 'lowest paid CEO in the whole industry' as he raises concerns surrounding Brexit

Pascal Soriot, the Chief Executive Officer of the Anglo-Swedish multinational AstraZeneca, has raised concerns that he is being underpaid, despite earning nearly £10 million each year.

2. Working Life: Jean-Christophe Tellier, CEO of UCB Pharma

Just as his company announced robust H1 2018 financials, UCB's Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of the tough life of a pharma CEO, as well as the path he took to get there.

1. Novartis cuts more than 2500 jobs in Switzerland and the UK

Swiss multinational Novartis are set to cut thousands of jobs across Europe in an effort to boost profitability. The move comes as part of a major restructuring which will take place over the next four years.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches